Introduction
============

Breast cancer (BC) is the most common malignant tumor and the primary cause of cancer-associated mortality in women worldwide ([@b1-ol-0-0-10187]). Although numerous treatments, including chemotherapy, radiotherapy, endocrine therapy and targeted therapy, are currently available for BC, the response of patients greatly varies partly due to their own antitumor immunity ([@b2-ol-0-0-10187]). Accumulating evidence suggests that adaptive immunity mediated by T and B lymphocytes provides the critical foundation for effective and sustained antitumor responses. Tumor-infiltrating lymphocytes (TILs) are likely to be the most relevant indicator of tumor immunity in solid tumors, with prognostic value ([@b3-ol-0-0-10187]). In BC, extensive tumor infiltration by cytotoxic CD8^+^ T cells is markedly associated with patient survival ([@b4-ol-0-0-10187],[@b5-ol-0-0-10187]) and response to therapy ([@b6-ol-0-0-10187]). Furthermore, the baseline expression of TILs can predict the pathological complete response (pCR) result following neoadjuvant chemotherapy in patients with BC ([@b7-ol-0-0-10187]), which is an important prognostic indicator.

Previous studies revealed that the composition of the gastrointestinal microbiome is a major environmental factor that varies among individuals, which may affect systemic immunity ([@b8-ol-0-0-10187],[@b9-ol-0-0-10187]). The gastrointestinal microbiome has been demonstrated to initiate the differentiation of T cells, the expansion of specific molecular subsets ([@b10-ol-0-0-10187],[@b11-ol-0-0-10187]) and the activation state of innate antigen-presenting cells (APCs), which may eventually affect priming of the systemic immune response ([@b12-ol-0-0-10187],[@b13-ol-0-0-10187]). In addition, the gastrointestinal microbiome may improve the outcomes of cancer treatment by impairing inflammatory activation in response to different therapeutic protocols ([@b14-ol-0-0-10187]). Numerous studies have confirmed the association between the gastrointestinal microbiome and tumors, particularly in colon carcinoma ([@b15-ol-0-0-10187]--[@b17-ol-0-0-10187]). However, for extraintestinal tumors, to the best of our knowledge, such an association has not been established. The present study aimed to assess whether the diversity of the gastrointestinal microbiome was associated with different expression patterns of TILs in patients with BC.

Materials and methods
=====================

### Patients

Between March 2017 and October 2017, a total of 90 biopsy-confirmed female patients with BC were enrolled in the present study at the Breast Center of The Fourth Hospital of Hebei Medical University (Shijiazhuang, China). All patients were first treated by chemotherapy, followed by surgical treatment, as appropriate. Available clinicopathological data included age, staging, menstrual state, estrogen receptor (ER) and/or progesterone receptor (PgR) status, human epidermal growth factor receptor 2 (HER2) status, TIL classification, and pCR cases. ER and PgR were assessed as positive if ≥1% of tumor cells exhibited nuclear staining ([@b18-ol-0-0-10187]). HER2-positive status was defined as a score of 3+ based on immunohistochemistry assay or HER2 gene amplification using fluorescent in situ hybridization, as described previously ([@b19-ol-0-0-10187]). The Miller-Payne grading system was used to evaluate the pathological response in surgical specimens ([@b20-ol-0-0-10187]), and pCR was defined as the absence of residual invasive tumor cells in the breast and axillary lymph nodes (ypT0/is + ypN0) in surgical specimens. All procedures were supervised and approved by the Human Tissue Research Committee of The Fourth Hospital of Hebei Medical University, and informed consent was provided by all participants.

### Assessment of TILs using a three-grade scale

Core needle biopsy was performed in the examination room. Briefly, between three and five lump tissues were obtained from different directions to obtain a suitable number of tissue samples. Subsequently, the tissue strip was placed in 4% neutral formalin solution and sent to the Pathology Department. Evaluation of TILs on the core needle biopsy specimens was performed by two experienced pathologists who were familiar with the evaluation criteria recommended by the International TILs Working Group in 2014 ([@b21-ol-0-0-10187]). The whole slide was screened using a low-power field, while an area with many lymphocytes was identified as a 'hotspot'. TILs were then evaluated by light microscopy in a medium-power field (magnification, ×100). The region of interest was restricted within the tumor borders as described by Salgado et al ([@b21-ol-0-0-10187]). TIL score was defined as the proportion of the area infiltrated by lymphocytes within the tumor itself plus the adjacent stroma, and the scores were classified as low (\<10), intermediate (10--50) and high (\>50%), accordingly ([@b22-ol-0-0-10187]).

### 16S ribosomal DNA (rDNA) amplification

Fresh fecal samples were collected from the 90 patients with BC and stored at −80°C. DNA was extracted from all samples using a ProbeGene^®^ Soil genomic DNA extraction kit (ProbeGene, Jiangsu, China) according to the manufacturer\'s protocol, and purified DNA was stored at −80°C prior to further analysis.

The 16S rDNA V3-V4 region of the ribosomal RNA gene was amplified by polymerase chain reaction using primers 341F (5′-CCTACGGGNGGCWGCAG-3′) and 806R (5′-GGACTACHVGGGTATCTAAT-3′), where the barcode was an eight-base sequence unique to each sample. Polymerase chain reaction was performed in a 50-µl reaction system consisting of 5 µl 10X KOD buffer, 5 µl 2.5 mM deoxyribonucleotide triphosphates, 1.5 µl of each primer (5 µM), 1 µl KOD polymerase (Toyobo (Shanghai) Co., Ltd., Shanghai, China) and 100 ng template DNA. Briefly, following a denaturation step at 95°C for 2 min, the amplifications were carried out with 27 cycles at a melting temperature of 98°C for 10 sec, an annealing temperature of 62°C for 30 sec, and an extension temperature of 68°C for 30 sec, followed by a final extension step at 68°C for 10 min. Each experiment was conducted in triplicate. Amplicons were subjected to electrophoresis on 2% agarose gels, purified using the AxyPrep DNA Gel Extraction kit (Axygen; Corning Inc., Corning, NY, US), according to the manufacturer\'s protocol, and semi-quantified using the QuantiFluor dsDNA system (Promega Corporation, Madison, WI, US). Purified amplicons were pooled in equimolar concentrations and underwent paired-end sequencing (2×250) on the Illumina HiSeq2500 platform (Illumina, Inc., San Diego, CA, USA) according to the manufacturer\'s protocols.

### Statistical analysis

Statistical analysis was performed using SPSS 23.0 software (SPSS, Inc., Chicago, IL, USA). Clinical characteristics, including age, menopausal state, staging, level of HER2 and ER/PgR expression, were analyzed using a χ^2^ test. P\<0.05 was considered to indicate a statistically significant difference.

Raw data from Illumina sequencing contain adapters or low-quality reads that may affect subsequent data assembly and analysis. Therefore, to obtain high-quality clean reads, raw reads were filtered according to the following criteria: i) Reads containing \>10% unknown nucleotides were removed; and ii) reads containing \<80% high-quality bases (Q-value, \>20) were excluded.

Paired-end clean reads were merged as raw tags using FLASH v1.2.11 ([@b23-ol-0-0-10187]) with a minimum overlap of 10 bp and a mismatch error rate of 2%. Noisy sequences of raw tags were filtered by QIIME v1.9.1 ([@b24-ol-0-0-10187]) pipeline under specific filtering conditions ([@b25-ol-0-0-10187]). Clean tags were searched against the reference database (<http://drive5.com/uchime/uchime_download.html>) to perform reference-based chimera detection using the UCHIME algorithm (<http://www.drive5.com/usearch/manual/uchime_algo.html>). All chimeric tags were removed, and effective tags were finally obtained for further analysis.

The effective tags were clustered into operational taxonomic units (OTUs) of ≥97% similarity using the UPARSE ([@b26-ol-0-0-10187]) pipeline. The tag sequence with highest abundance was selected as a representative sequence within each cluster. Venn analysis was performed among groups to identify unique and common OTUs. The representative sequences were classified into organisms by a naive Bayesian model using RDP classifier v2.2 ([@b27-ol-0-0-10187]) based on the Greengenes ([@b28-ol-0-0-10187]) database (<https://www.arb-silva.de/>). Weighted and unweighted UniFrac distance matrices were generated using QIIME for β-diversity analysis. Between-group comparison of β-diversity was performed using Welch\'s t-test and Wilcoxon rank test in R. β-diversity comparison among groups was computed using Tukey\'s HSD test and Kruskal-Wallis H test in R. Analysis of similarity (ANOSIM) was used to test whether the differences among groups were significantly greater than those within groups. Biomarker features in each group were screened by Metastats software (v.20090414) ([@b29-ol-0-0-10187]).

Results
=======

### Clinical characteristics

A total of 80 patients were included in the present study (10 cases were unavailable since mass was removed in another hospital or the biopsy section could not be found) and divided into three groups as follows: High expression of TILs (TIL-H; n=21), medium expression of TILs (TIL-M; n=34) and low expression of TILs (TIL-L; n=25). Associations between TIL distribution and clinical characteristics, including age, menstrual status, staging, HER2 expression and ER/PgR expression, were assessed ([Table I](#tI-ol-0-0-10187){ref-type="table"}). Only the expression status of HER2 was positively associated with TIL distribution (P=0.037). A total of 58 patients who underwent surgery following chemotherapy (20 from TIL-H group, 22 from TIL-M group and 16 from TIL-L group) were evaluated for chemotherapy efficiency ([Table II](#tII-ol-0-0-10187){ref-type="table"}).

### Analysis of species differences

There were 3,174, 2,996 and 2,877 different OTUs in the TIL-H, TIL-M and TIL-L groups, respectively. The number of common and unique OTUs is shown in [Fig. 1A](#f1-ol-0-0-10187){ref-type="fig"}, and [Fig. 1B](#f1-ol-0-0-10187){ref-type="fig"} shows the top 10 species and their abundances. [Tables III](#tIII-ol-0-0-10187){ref-type="table"} and [IV](#tIV-ol-0-0-10187){ref-type="table"} illustrated that the gastrointestinal microbiome, when compared among the three groups (TIL-L vs. TIL-M vs. TIL-H) or compared between the TIL-L and TIL-H groups, exhibited significantly different β-diversities in weighted and unweighted UniFrac analyses, which suggested that low expression of TILs was associated with lower β-diversity (P\<0.01). Furthermore, ANOSIM revealed a greater intergroup difference between the TIL-L and TIL-H groups compared with the intragroup difference, which indicated that the grouping was correct (P=0.042; [Fig. 2](#f2-ol-0-0-10187){ref-type="fig"}).

### Relative abundance of microbiota in TIL-H and TIL-L groups

The different distributions of microbiota in TIL-H and TIL-L groups were assessed using Metastats software. [Table V](#tV-ol-0-0-10187){ref-type="table"} demonstrated that At the genus level, patients in the TIL-L group had higher abundances of Mycobacterium, Rhodococcus, Catenibacterium, Bulleidia, Anaerofilum, Sneathia, Devosia and TG5, but lower abundances of Methanosphaera and Anaerobiospirillum compared with the TIL-H group (P\<0.05). At the species level, the abundances of stercoris, barnesiae, coprophilus, flavefaciens and C21_c20 were greater in the TIL-L group, while the abundances of producta and komagatae were greater in the TIL-H group (P\<0.05).

Discussion
==========

Recently, increasing attention has been paid to the effects of the gastrointestinal microbiome on human diseases. Diversity of the gastrointestinal microbiome is closely associated with human health, including immunity, digestion, obesity ([@b30-ol-0-0-10187]), diabetes ([@b31-ol-0-0-10187],[@b32-ol-0-0-10187]), heart disease ([@b33-ol-0-0-10187],[@b34-ol-0-0-10187]), acquired immune deficiency syndrome ([@b35-ol-0-0-10187]) and cancer ([@b36-ol-0-0-10187],[@b37-ol-0-0-10187]).

The present study demonstrated that the gastrointestinal microbiome was distinctly diverse and compositionally different among different TIL expression groups of patients with BC. Higher TIL expression was associated with a greater diversity of the gastrointestinal microbiome in the present study. A previous study only suggested that patients with BC possess statistically different microbiota composition compared with controls ([@b38-ol-0-0-10187]), and the gastrointestinal microbiome is associated with the clinical or biological characteristics of patients with BC ([@b38-ol-0-0-10187],[@b39-ol-0-0-10187]). However, the present study revealed that microbiome diversity was associated with TIL distribution. Additionally, differentially expressed microbiota species among different TIL groups were identified. Among the gastrointestinal microbiome, *barnesiae* and *coprophilus* belong to the genus *Bacteroides* that can modulate estrogen metabolism and function as a risk factor for BC ([@b40-ol-0-0-10187]--[@b43-ol-0-0-10187]); in this study, higher abundance of *barnesiae* was associated with the low expression of TILs., indicating *barnesiae* could be a risk factor for BC. The mechanism underlying *barnesiae*-modulated estrogen metabolism in response to immunity modification in BC remains unclear. The state of TIL expression *in situ* exhibits a strong association with the outcomes and treatment efficiency of patients with BC, and the gastrointestinal microbiome can regulate immune activation, following treatment with chemotherapeutic agents ([@b14-ol-0-0-10187],[@b44-ol-0-0-10187]--[@b46-ol-0-0-10187]). The results of the present study revealed that greater quantity and abundance of the gastrointestinal microbiome were positively associated with the expression of TILs, demonstrating an internal link between the microbiome and immunity in the pathogenesis of BC. Therefore, the treatment efficiency should be assessed in a cohort consisting of large-scale samples.

Patients with triple-negative BC and HER2-positive BC may benefit from neoadjuvant chemotherapy ([@b47-ol-0-0-10187]), and the data of the present study revealed that HER2 expression was positively associated with high TIL expression. Furthermore, patients with high TIL expression exhibited good outcomes following chemotherapy. All these findings implied an inherent link among microbiome, immunity and treatment efficiency in patients with BC.

The small sample size is the main limitation of the present study. Additionally, further studies regarding the mechanism need to be performed in the future. In these, a BC mouse model will be established to verify the conclusions of the present study by altering the gastrointestinal microbiome.

In conclusion, expression levels of TILs were associated with the diversity of the gastrointestinal microbiome in patients with BC. The results of the present study suggested that the gastrointestinal microbiome may affect the prognosis of patients with BC by interacting with TIL expression.
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![Operational taxonomic unit quantitative differences and species distribution stacking maps for the three groups. (A) Each point represents a group, and the lines between points represent the intersection of two points. (B) Species composition of each sample at the species level was assessed; the species abundance of different samples is presented. Only the top 10 species are shown, while the remaining species were classified into the 'others' category. Tags that could not be annotated at that level were classified into the 'unclassified' category. H, high; L, low; M, medium; TIL, tumor-infiltrating lymphocytes.](ol-17-06-5050-g00){#f1-ol-0-0-10187}

![When comparing intragroup and intergroup Ranks mean values, information of grouping differences can be obtained using a box diagram method. When the dissimilarity rank between the groups was higher than that within the groups, the intergroup difference was greater than the intragroup difference. H, high; L, low; TIL, tumor-infiltrating lymphocytes.](ol-17-06-5050-g01){#f2-ol-0-0-10187}

###### 

Clinical characteristics associated with TILs.

                     No. of cases                     
  ------------------ -------------- ---- ---- ------- -------
  Age (years)                                 0.541   0.736
    \<45             7              14   7            
    45--59           6              12   12           
    ≥60              7              8    6            
  Staging                                     2.701   0.259
    I                0              0    0            
    II               7              5    7            
    III              11             20   12           
    IV               3              9    6            
  Menopausal state                            0.269   0.874
    Yes              11             19   15           
    No               10             15   10           
  HER2                                        6.597   0.037
    Positive         6              7    13           
    Negative         15             26   12           
  ER/PgR                                      3.251   0.197
    Positive         18             25   15           
    Negative         3              8    10           

ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PgR, progesterone receptor; TIL, tumor-infiltrating lymphocytes.

###### 

Comparison of pCR of patients in the TIL-H group and patients in the other two groups.

  Patients   TIL-low and TIL-medium   TIL-H   χ^2^    P-value
  ---------- ------------------------ ------- ------- ---------
  pCR            2                        4   3.015   0.082
  Non-pCR    36                       16              

H, high; pCR, pathological complete response; TIL, tumor-infiltrating lymphocytes.

###### 

Weighted UniFrac distance difference analysis.

  Groups                      Test method                           P-value
  --------------------------- ------------------------------------- -----------------------------------------------------------
  TIL-L vs. TIL-M             t-test                                0.0004^[a](#tfn3-ol-0-0-10187){ref-type="table-fn"}^
  TIL-L vs. TIL-M             Wilcoxon                              0.0001^[a](#tfn3-ol-0-0-10187){ref-type="table-fn"}^
  TIL-L vs. TIL-H             t-test                                1.0147×10^−6[a](#tfn3-ol-0-0-10187){ref-type="table-fn"}^
  TIL-L vs. TIL-H             Wilcoxon                              1.8884×10^−7[a](#tfn3-ol-0-0-10187){ref-type="table-fn"}^
  TIL-M vs. TIL-H             t-test                                0.1227
  TIL-M vs. TIL-H             Wilcoxon                              0.1245
  TIL-L vs. TIL-M vs. TIL-H   Kruskal-Wallis                        7.2565×10^−7[a](#tfn3-ol-0-0-10187){ref-type="table-fn"}^
  TIL-L vs. TIL-M vs. TIL-H   Tukey honest significant difference   7.0541×10^−7[a](#tfn3-ol-0-0-10187){ref-type="table-fn"}^

P≤0.01. H, high; L, low; M, medium; TIL, tumor-infiltrating lymphocytes.

###### 

Unweighted UniFrac distance difference analysis.

  Groups                      Test method                           P-value
  --------------------------- ------------------------------------- ------------------------------------------------------------
  TIL-L vs. TIL-M             t-test                                0.4007
  TIL-L vs. TIL-M             Wilcoxon                              0.1997
  TIL-L vs. TIL-H             t-test                                1.2397×10^−12[a](#tfn4-ol-0-0-10187){ref-type="table-fn"}^
  TIL-L vs. TIL-H             Wilcoxon                              7.5180×10^−12[a](#tfn4-ol-0-0-10187){ref-type="table-fn"}^
  TIL-M vs. TIL-H             t-test                                4.9195×10^−12[a](#tfn4-ol-0-0-10187){ref-type="table-fn"}^
  TIL-M vs. TIL-H             Wilcoxon                              2.9383×10^−12[a](#tfn4-ol-0-0-10187){ref-type="table-fn"}^
  TIL-L vs. TIL-M vs. TIL-H   Kruskal-Wallis                        7.0570×10^−14[a](#tfn4-ol-0-0-10187){ref-type="table-fn"}^
  TIL-L vs. TIL-M vs. TIL-H   Tukey honest significant difference   1.9653×10^−15[a](#tfn4-ol-0-0-10187){ref-type="table-fn"}^

P≤0.01. H, high; L, low; M, medium; TIL, tumor-infiltrating lymphocytes.

###### 

Bacterial species exhibiting significant alterations in relative abundance between TIL-H and TIL-L groups.

  Phylum           Class                 Order                Family                    Genus                  Species          Mean, TIL-L (%)   Mean, TIL-H (%)   P-value       FDR
  ---------------- --------------------- -------------------- ------------------------- ---------------------- ---------------- ----------------- ----------------- ------------- -------------
  Actinobacteria   Actinobacteria        Actinomycetales      Mycobacteriaceae          *Mycobacterium*                         1.35×10^−5^       0                 7.97×10^−6^   0.001752485
  Actinobacteria   Actinobacteria        Actinomycetales      Nocardiaceae              *Rhodococcus*                           7.45×10^−6^       0                 0.000872455   0.01998002
  Actinobacteria   Coriobacteriia        Coriobacteriales     Coriobacteriaceae         *Collinsella*          *Stercoris*      7.11×10^−5^       0                 0.000999001   0.01998002
  Bacteroidetes    Bacteroidia           Bacteroidales        Bacteroidaceae            *Bacteroides*          *Barnesiae*      9.69×10^−5^       0                 0.000999001   0.01998002
  Bacteroidetes    Bacteroidia           Bacteroidales        Bacteroidaceae            *Bacteroides*          *Coprophilus*    0.012465402       5.90×10^−5^       0.002997003   0.038784745
  Euryarchaeota    Methanobacteria       Methanobacteriales   Methanobacteriaceae       *Methanosphaera*                        0                 5.40×10^−6^       0.001388066   0.025447882
  Firmicutes       Erysipelotrichi       Erysipelotrichales   Erysipelotrichaceae       *Catenibacterium*                       7.09×10^−5^       0                 0.000999001   0.01998002
  Firmicutes       Clostridia            Clostridiales        Lachnospiraceae           *Blautia*              *Producta*       2.71×10^−5^       0.000354621       0.000999001   0.01998002
  Firmicutes       Erysipelotrichi       Erysipelotrichales   Erysipelotrichaceae       *Bulleidia*                             6.88×10^−6^       0                 0.001908364   0.032295398
  Firmicutes       Clostridia            Clostridiales        Ruminococcaceae           *Anaerofilum*                           1.43×10^−5^       2.46×10^−6^       0.002518182   0.037610265
  Firmicutes       Clostridia            Clostridiales        Ruminococcaceae           *Ruminococcus*         *Flavefaciens*   1.04×10^−5^       9.19×10^−7^       0.002735292   0.037610265
  Fusobacteria     Fusobacteriia         Fusobacteriales      Leptotrichiaceae          *Sneathia*                              2.31×10^−5^       0                 0.000999001   0.01998002
  Proteobacteria   Alphaproteobacteria   Rhizobiales          Hyphomicrobiaceae         *Devosia*                               1.05×10^−5^       0                 3.81×10^−5^   0.004192394
  Proteobacteria   Deltaproteobacteria   Desulfovibrionales   Desulfovibrionaceae       *Desulfovibrio*        *C21_c20*        9.42×10^−6^       0                 0.00018235    0.013372361
  Proteobacteria   Gammaproteobacteria   Aeromonadales        Succinivibrionaceae       *Anaerobiospirillum*                    0                 1.25×10^−5^       0.000999001   0.01998002
  Proteobacteria   Alphaproteobacteria   Rhizobiales          Methylobacteriaceae       *Methylobacterium*     *Komagatae*      0                 4.99×10^−6^       0.00262006    0.037610265
  Synergistetes    Synergistia           Synergistales        Dethiosulfovibrionaceae   *TG5*                                   7.16×10^−6^       8.63×10^−7^       0.000499914   0.01998002

The difference of microbial community abundance between the two groups was tested using the Metastats software. The P-value was obtained, then the Q-value was corrected by FDR, and the significance of the difference was evaluated by screening the P-value or Q-value. P≤0.05 indicated a statistically significant difference. FDR, false discovery rate; H, high; L, low; TIL, tumor-infiltrating lymphocytes.
